133 results about "Tinidazole" patented technology

The present invention refers to a treatment for mixed infectious diseases in the human reproductive system, wherein an association of compounds containing fluconazole and either tinidazole is used, the same being associated in doses lower to those commonly used therapeutically. The combination has proven to be highly efficacious and shown a good degree of tolerance.

The present invention relates to a method for determining 10 kinds of antibiotics in a water environment through combination of a sample pre-treatment technology and HPLC-MS, and belongs to the field of detection of safety of trace organic contaminant residue in the water environment. The method is characterized in that a water sample is separated and enriched through combination of solid phase extraction and dispersive liquid-liquid microextraction (SPE-DLLME), and then an ultra-high performance liquid chromatography-mass spectrometry instrument (UPLC-MS/MS) is adopted as a detection tool to directly determine the contents of 10 kinds of common antibiotics in the water environment (drinking water, tap water, river water, sewage treatment plant influent and effluent), wherein the 10 kinds of the common antibiotics respectively are sulfadiazine, sulfamethoxazole, oxytetracycline, tetracycline, doxycycline, ciprofloxacin, levofloxacin, chloramphenicol, cefuroxime axetil and tinidazole. According to the present invention, the water sample pre-treatment method and the instrument detection conditions are investigated and optimized, and the optimal SPE-DLLME-UPLC-MS/MS method is established and is successfully applied for the real sample determination; and compared with the traditional method, the method of the present invention has advantages of high sensitivity, high extraction recovery rate, wide application objects, environmental protection, and the like.

Antimicrobial and contraceptive compositions and methods which prevent and/or reduce the risk of transmission of sexually transmitted diseases through sexual activity as well as prevent and/or reduce the risk of pregnancy are provided. The compositions contain (1) a matrix-forming agent, (2) a bio-adhesive agent, (3) a buffering agent, (4) optionally a humectant, (5) optionally a preservative, and (6) water; wherein the composition is suitable for application within the vagina; wherein the compositions form a semisolid matrix on contact with ejaculate (thereby trapping ejaculated microbes and spermatozoa); wherein the composition causes hardening of cervical mucus (thereby decreasing the probability of sperm entry); wherein the composition forms a bio-adhesive layer over vaginal surfaces (thereby preventing or reducing the risk of contact of STD-causing microbes with the vaginal surfaces); wherein the composition maintains an acidic vaginal pH of less than about 5 in the presence of semen ejaculated from the male; and wherein the composition does not significantly impair the natural microbiological balance within the vagina. The antimicrobial and contraceptive compositions may also contain additional antimicrobial and/or contraceptive agents (e.g., nonoxynol-9, octoxynol-9, benzalkonium chloride, phosphorylated hesperidins, sulfonated hesperidins, polystyrene sulfonates, substituted benzenesulfonic acid formaldehyde co-polymers, H2SO4-modified mandelic acids, povidone iodine, itraconazole, ketoconazole, metronidazole, clotrimazole, fluconazole, teraconazole, miconazole, tinidazole, iconazole, chloramphenicol, nystatin, cyclopiroxolamine, and the like).

The invention provides a nanometer montmorillonite sustained release agent of an azomycin medicament The sustained release agent is prepared by inserting 10 to 45 weight portions of the azomycin medicament into the interlayer of 100 weight portions of Na-montmorillonite in a protonizing way under the condition of the pH value of 1.0 to 5.0 by adopting a liquor intercalation method; the azomycin medicament is metronidazole or tinidazole; the Na-montmorillonite is obtained by using Na<+> to replace Ca<2+> and Mg<+2> in the material of montmorillonite. The sustained release agent takes the montmorillonite as the vector of the azomycin medicament, which not only has the effects of releasing the medicament and improving the targeting, but also combines the characteristic that the montmorillonite can absorb pathogens and toxins, and can greatly improve the concentration of the partial medicament in a body, thereby reducing the medication times and species of the medicament.

The invention relates to a preparation method of new preparation of erythrocin, which is characterized in that an endothelin core of erythrocin is prepared, and then an isolating layer, a protective layer, a second isolating layer and an improved enteric-coating material layer are applied one by one. In this way, new preparation of the erythrocin which has certain feature of releasing (dissolving) in acid solution (hydrochloric acid solution 9 to 1000) can be formed. The technology of the new preparation can also be widely applied to drugs which, like erythrocin, when being taken orally by a patient, cause the patient to suffer the side effects of stimulation, sickness and the like after degradation in the stomach of the patient or contact with the stomach of the patient, and drugs which the patient needs to take orally to let the blood concentration to reach the peak value in a short time. Such drugs include macrolides of azithromycin, metronidazole of nitroimidazoles, tinidazole, acyclovir as an antiviral drug, ammonium chloride as a phlegm eliminating drug, bromhexine, chloroquine as an antimalarial, nitroquine, artemisinin, dihydroartemisinin, artesunate, primaquine, pyrimethamine, carbarsone and emetine amebicides and so on.

The invention discloses a method for detecting nitroimidazole drugs and a dedicated enzyme-linked immune kit. The kit comprises a special antibody, and a coating antigen and an enzyme label; nitroimidazole is at least one of the following components: metronidazole, tinidazole, imetridazole and ronidazol. The method in the invention has the advantages of simple sample pretreatment process, simple operation, low cost, good specificity, high sensitivity, high accuracy, etc.; the method can perform on-site monitoring and is suitable for screening a plurality of samples. Therefore, the method and the dedicated kit in the invention play an important part in detecting the residues of the nitroimidazole drugs in animal derived food.

The present invention relates to a controlled release pharmaceutical composition comprising amounts ranging from about 0.1 to about 4.5% w/w, of one or more of rate controlling cellulosic ether polymers.

The invention discloses a tinidazole nano-composite silver micro-emulsified antibiotics, 0.10 to 1.50 units of tinidazole and 0.008 to 0.020 units of nano-silver being regarded as medical components, and 96.92 to 99.67 units of micro-emulsified substrate and 0.30 to 3.00 units of auxiliary materials are evenly mixed together with a certain percentage, then the tinidazole complex nano-silver micro-emulsified antibiotics can be got which has a yellow outlook, the diameter of grains is 1nm to 100nm, the invention is stable, which can not only disturb the synthesis of DNA, but also be able to combine with oxygen metabolic enzyme (-SH) to interrupt the respiration metabolism process, so as to kill the aerobic and anaerobic pathogens and improve the recovery of wounds, and diseases such as vaginitis, endometritis can be quickly and effectively cured, and the preparation method of the invention is simple and safe.

The invention relates to a tinidazole and sodium chloride injection and a preparation method thereof. The injection is prepared from the following raw materials in percentage by weight/volume: 0.4 percent of tinidazole, 0.9 percent of sodium chloride, 0.005 to 0.5 percent of stabilizer, 0.01 to 0.05 percent of activated carbon, a proper amount of pH value regulator (the pH value is 3.5 to 5.5), and the balance of water for injection. The preparation method comprises the following steps of: putting the sodium chloride into a thick mixing tank, stirring the sodium chloride and water and dissolving to form a solution at the concentration of between 20 and 22 percent (g/ml), adding 50 percent of the activated carbon, stirring, boiling, cooling, performing pressure filtration, performing internal circulation for 10 minutes, and transferring into a thin mixing pot; putting the tinidazole into a container, adding water, stirring and dissolving, and transferring into the thin mixing pot; putting the stabilizer into the thin mixing pot, adding water, adding the residual activated carbon, adding water until the mixture reaches certain volume, stirring, refluxing for 15 minutes, and regulating the pH value to be 3.5 to 5.5 by using the pH value regulator; sampling, detecting the sodium chloride and the tinidazole, and cooling to 20 to 40 DEG C after the content of the sodium chloride and the tinidazole is qualified; and sequentially performing four-stage filtration and filling, sterilizing at the temperature of 121 DEG C, and warehousing after the product is proved to be qualified through light inspection. The problems that a tinidazole and sodium chloride injection is low in clarity qualification rate and is easy to crystallize in winter are solved.

An aqueous nitroimidazole composition comprises metronidazole, tinidazole or a combination thereof at a concentration greater than the solubility of the free base form of the nitroimidazole in water at 20° C., and a nitroimidazole crystallization-inhibiting amount of at least one organic acid. The organic acid preferably is a lower alkyl carboxylic acid (e.g., acetic acid), a polybasic acid (e.g., citric acid, tartaric acid, malic acid, polyacrylic acid, and the like), or a combination thereof. The composition can further include a thickening agent, to form a gel. The composition is free from organic co-solvents, water-soluble vitamins, and cyclodextrins; and free from nitroimidazole crystals at an ambient temperature of about 20° C. Methods of preparing the composition are also described.

The invention discloses a tinidazole injection preparation which consists of the following components by weight percent: 0.3-0.8% of tinidazole, 0.9% of an osmotic pressure regulating agent, 0.25-0.5% of an absorbing agent, and the balance of injection water to achieve 100%, wherein pH value is regulated to be 4.0-4.2 through a pH regulating additive. Furthermore, the invention discloses a preparation method of the tinidazole injection preparation. According to the tinidazole injection preparation and the preparation method thereof, problems of high raw material consumption and low qualification rate of the tinidazole injection in production process can be effectively solved, so that an expected effect is achieved. According to the tinidazole injection preparation and the preparation method, by regulating dosages and percents of the absorbing agent and the osmotic pressure regulating agent in the formula as well as regulating main drug dissolving temperature and two absorbing time limits of the absorbing agent, the quality of a product can effectively guaranteed, and the production cost is reduced. And the tinidazole injection preparation disclosed by the invention is simple in formula, high in yield, and stable and reliable, and can implement industrial mass production conveniently.

The invention relates to a preparation method of tinidazole sodium chloride injection, which comprises the steps of concentrated preparation, heating, filtration, dilution, adjustment of pH value, filtration, filling, sealing, sterilization, inspection and the like. The tinidazole sodium chloride injection prepared by the preparation method has good stability and can be packaged in plastic bottles.

The invention discloses mouth wash, and belongs to the technical field of daily chemical products. The mouth wash is prepared from the following raw materials in parts by weight: 20-25 parts of radix zanthoxyli, 10-20 parts of pseudo-ginseng leaves, 10-12 parts of momordica grosvenori, 15-20 parts of lotuses, 5-8 parts of green tea, 0.5-1 part of polyphenols of grapevines, 1-5 parts of sodium chloride and 100 parts of deionized water. According to the mouth wash disclosed by the invention, active ingredients are extracted from Chinese herbal medicines of natural raw materials and are combined for use, so that the prepared mouth wash has the effects of cleaning, proofing moths, stopping bleeding and whitening; natural plant raw materials are adopted, so that the mouth wash does not contain chemical substances such as triclosan or metronidazole, tinidazole, hydrogen peroxide, an iodine solution, alcohol and the like, can be used for daily oral cavity nursing, and is easier to accept because of sweetness and faint scent.

The invention relates to a compound ear drop for treating otitis externa mycotica, in particular to an ear drop for treating otitis externa mycotica. The drop is prepared by the the following ingredients: 3-30g of fluconazol, 5-50g of tinidazole, 3-30g of menthol, 100-800g of glycerine, 30-200ml of alcohol, 5-100ml of 1mol/L sodium hydroxide solution, and 1000ml of distilled water. The drop contains both antifungal drug and antianaerobic drug which enable the ear drop to have both antifungal activity and antianaerobic activity. In the process of preparation allocation, the tinidazole being slightly soluble into water need be heated by aqueous bath to be dissolved, the fluconazol and the menthol are easily dissolved into the alcohol. The alcohol is used for not only dissovling both the fluconazol and the menthol, but also being taken a transdermal accelerant of the ear drop, as well as drying the external acoustic meatus. The menthol can dispel wind to make the skin and the membrana mucosa cool and relieve the complaint and pain. A fixed amount of glycerine can protect the ear mucosa and keep the preparation tensile and adhesive.

The invention provides a tinidazole liposome injection and a preparation method thereof. The tinidazole liposome injection is characterized by comprising the following components by weight portion: 1 portion of tinidazole, 2-10 portions of phospholipid, 0.5-3 portions of cholesterol, 2-5 portions of tween 80 and 1-2 portions of sodium deoxycholate. The tinidazole liposome injection is prepared through reverse phase evaporation according to the proportion of specific auxiliary materials to raw auxiliary materials and achieves the unexpected effect on solving the problems of poor stability and crystallization of tinidazole injection.

The invention discloses externally-applied skin gel as well as a preparation method and application thereof, belongs to the technical field of medicines and relates to preparation of the externally-applied skin gel from calcium dobesilate and any one active pharmaceutical ingredient of metronidazole, tinidazole and ornidazole for the first time. In weight, per 100.0g of externally-applied skin gel contains 1.0g to 8.0g of calcium dobesilate and 0.1g to 3.0g of metronidazole, or tinidazole or ornidazole. The externally-applied skin gel can be used for treating acne rosacea and acne; the calcium dobesilate in the gel can be used for improving the blood circulation of skin and reducing the telangiectasis of the skin; and metronidazole, or tinidazole or ornidazole has an effect of exterminating worms and mites on the skin.

A process for preparing tinidazole from ethiol and chloroethanol includes removing sodium at ordinary temp-100 deg.C in alkaline condition, vacuum distilling to obtain beta-hydroxyethioether, condensation reaction on 2-methyl-5-nitroimidazole in methyl substituted 2-pentone under action of ZnCl2 and sodium chloride to obtain 1-(beta-ethioethyl)-2-methyl-5-nitroimidazole, and catalytic oxidizing by hydrogen peroxide and concentrated sulfuric acid. Its advantages are high output rate, low cost and less environmental pollution.

The invention discloses gargle. The gargle comprises 0.5-1.2 parts of paeonol, 0.6-1.0 part of eucalyptus oil, 0.8-1.5 parts of eugenol, 0.05-0.1 part of borax, 0.1-0.5 part of epsilon-polylysine, 0.04-0.09 part of borneolum syntheticum, 0.05-0.1 part of menthol, 0.05-0.08 part of natamycin, 20-27 parts of propylene glycol, 15-21 parts of hydrogenated castor oil [PEG-40 (polyethylene glycol-40)], 0.02-0.04 part of citric acid, 1.0-1.9 parts of sweetening agents and 45-62 parts of deionized water. The gargle has the advantage that strong effects of inhibiting pyogenic bacteria in oral cavities still can be realized by the gargle without chemical components such as alcohol, cetylpyridinium chloride, chlorhexidine and triclosan or hormone such as metronidazole and tinidazole under the condition of low usage of the borax.

The invention relates to a new method for synthesizing an ornidazole derivative, namely benzoyl ornidazole. At present, ornidazole is a third-generation novel nitroimidazole derivative after metronidazole and tinidazole, has high anaerobe resistance and protozoan resistance, but is difficultly applied to children because of bitter taste. The invention aims to provide a new method for synthesizing the ornidazole derivative. The synthesis method comprises the following steps of: adding ornidazole, fatty acid and fatty alcohol ester, and aliphatic tertiary amine or nitrogen heterocycle organic base in turn, stirring for dissolution and clarification, heating to refluxing temperature, dripping benzoyl chloride, and reacting by keeping temperature under normal pressure; cooling, adding water, stirring, standing for demixing, adding water to wash an organic phase, cooling and freezing for crystallization, filtering, washing, and drying to obtain a crude product; and recrystallizing the crude product by using ethanol to obtain the benzoyl ornidazole. The method has the advantages that: the obtained benzoyl ornidazole is a precursor medicine of ornidazole, the original bitter taste of the ornidazole is eliminated, and a method for industrially producing the benzoyl ornidazole is realized.

An oral medicine in the form of tablet, buccal lozenge, film, or gargle for treating foul breath, periodontal abscess, pericoronitis, recurrent aphtha, etc contains the antibacterial medicine (levofloxacin and tinidazole) and menthol.

The invention discloses a UHPLC-MS/MS (Ultra High Performance Liquid Chromatography-Mass Spectrometry-Mass Spectrometry) analytical method for measuring rat curcumin plasma concentration. The method comprises the following steps: (1) preparing a curcumin standard solution and an internal standard tinidazole standard solution, and establishing a standard curve; and (2) adding an internal standard into to-be-measured plasma, performing pretreatment, performing LC-MS/MS analysis, and calculating the concentration of curcumin in the to-be-measured plasms by utilizing the standard curve. According to the method disclosed by the invention, the chromatographic conditions and internal standard substances are reasonably selected, the sensitivity is improved, the analysis time is shortened, and the sample pretreatment process is simplified. Meanwhile, the method disclosed by the invention has high accuracy and precision degree, and the detection requirements of non-clinical pharmacokinetic study are met.